Suspended, active non-recruiting and recruiting oncological phase 1, 2, 3 clinical trials respectively throughout the world from the beginning of pandemic to the first six months of 2022 (30/01/2020 to 30/06/2022)
Study status
Phase 1
Phase 2
Phase 3
Suspended
33
41
5
Active, non-recruiting
236
357
118
Recruiting
2,368
3,474
818
Total
3,592
5,466
1,464
Declarations
Author contributions
RB and ZB: Conceptualization. ZB, AL, MB, and VA: Methodology. VA, GR, VT, LM, and CC: Data curation. VA and ZB: Writing—original draft, Writing—review & editing. RB: Supervision. All authors have read and agreed to the published version of the manuscript.
Conflicts of interest
RB is a consultant/advisory board member for AstraZeneca, Boehringer Ingelheim, Novartis, MSD, Otsuka, Eli-Lilly, Roche, Amgen, GSK, Eisai, Bristol Myers Squibb. ZB is a consultant/advisory board member for Daichii Sanchyo. All other authors declare that they have no conflicts of interest.
North CM, Dougan ML, Sacks CA. Improving clinical trial enrollment—in the Covid-19 era and beyond.N Engl J Med. 2020;383:1406–8. [DOI] [PubMed]
Ndumele A, Park KU. The impact of COVID-19 on national clinical trials network breast cancer trials.Curr Breast Cancer Rep. 2021;13:103–9. [DOI] [PubMed] [PMC]
Ballatore Z, Merloni F, Ranallo N, Bastianelli L, Vitarelli F, Cantini L, et al. Cancer patient perspective in the arena of COVID-19 pandemic.Psychooncology. 2022;31:39–45. [DOI] [PubMed] [PMC]
de Joode K, Dumoulin DW, Engelen V, Bloemendal HJ, Verheij M, van Laarhoven HWM, et al. Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients’ perspective.Eur J Cancer. 2020;136:132–9. [DOI] [PubMed] [PMC]
Al-Quteimat OM, Amer AM. The impact of the COVID-19 pandemic on cancer patients.Am J Clin Oncol. 2020;43:452–5. [DOI] [PubMed] [PMC]
Apisarnthanarak A, Siripraparat C, Apisarnthanarak P, Ullman M, Saengaram P, Leeprechanon N, et al. Patients’ anxiety, fear, and panic related to coronavirus disease 2019 (COVID-19) and confidence in hospital infection control policy in outpatient departments: a survey from four Thai hospitals.Infect Control Hosp Epidemiol. 2021;42:1288–90. [DOI] [PubMed] [PMC]
Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak.Cancer Discov. 2020;10:783–91. [DOI] [PubMed] [PMC]
Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies.Am Soc Clin Oncol Educ Book. 2016;35:185–98. [DOI] [PubMed] [PMC]
Unger JM, Blanke CD, LeBlanc M, Hershman DL. Association of the coronavirus disease 2019 (COVID-19) outbreak with enrollment in cancer clinical trials.JAMA Netw Open. 2020;3:e2010651. [DOI] [PubMed] [PMC]
NCTN group chairs: cancer trials take backseat to clinical care amid COVID-19 pandemic [Internet].The Cancer Letter Inc.; c2023 [cited 2022 Jul 5]. Available from: https://cancerletter.com/articles/20200410_1/
Upadhaya S, Yu JX, Oliva C, Hooton M, Hodge J, Hubbard-Lucey VM. Impact of COVID-19 on oncology clinical trials.Nat Rev Drug Discov. 2020;19:376–7. [DOI] [PubMed]
Patil R, Varner C. Delivering clinical trial continuity during COVID-19. IQVIA; 2020.
Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al.; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.Lancet. 2020;395:1907–18.Erratum in: Lancet. 2020;396:758. [DOI] [PubMed] [PMC]
Agostinelli V, De Filippis C, Torniai M, Rocchi MBL, Pagliacci A, Ricci G, et al. Primum non nocere: how to ensure continuity of care and prevent cancer patients from being overlooked during the COVID-19 pandemic.Cancer Med. 2023;12:1821–8. [DOI] [PubMed] [PMC]
Hall E, Lewis R, Snowdon C. Life after COVID-19 for cancer clinical trials.Int J Radiat Oncol Biol Phys. 2020;108:486–8. [DOI] [PubMed] [PMC]
Fontana E, Arkenau HT. Oncology clinical trials during the COVID-19 outbreak: lessons learnt during the crisis and future opportunities.Cancer Treat Rev. 2020;88:102047. [DOI] [PubMed] [PMC]
Caldarella C, Cocciolillo F, Taralli S, Lorusso M, Scolozzi V, Pizzuto DA, et al. The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study.Eur J Nucl Med Mol Imaging. 2022;49:1623–9. [DOI] [PubMed] [PMC]
Waterhouse DM, Harvey RD, Hurley P, Levit LA, Kim ES, Klepin HD, et al. Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American Society of Clinical Oncology Survey.JCO Oncol Pract. 2020;16:417–21. [DOI] [PubMed]
Tolaney SM, Lydon CA, Li T, Dai J, Standring A, Legor KA, et al. The impact of COVID-19 on clinical trial execution at the Dana-Farber cancer institute.J Natl Cancer Inst. 2021;113:1453–9. [DOI] [PubMed] [PMC]
Perez-Gracia JL, Awada A, Calvo E, Amaral T, Arkenau HT, Gruenwald V, et al. ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy.ESMO Open. 2020;5:e000662. [DOI] [PubMed] [PMC]
Gregucci F, Caliandro M, Surgo A, Carbonara R, Bonaparte I, Fiorentino A. Cancer patients in Covid-19 era: swimming against the tide.Radiother Oncol. 2020;149:109–10. [DOI] [PubMed] [PMC]
Massari F, Mollica V, Salvagni S, Tognetto M, Ardizzoni A. Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients’ care.Future Oncol. 2020;16:1413–5. [DOI] [PubMed] [PMC]
Asaad M, Habibullah NK, Butler CE. The impact of COVID-19 on clinical trials.Ann Surg. 2020;272:e222–3. [DOI] [PubMed] [PMC]
Nabhan C, Choueiri TK, Mato AR. Rethinking clinical trials reform during the COVID-19 pandemic.JAMA Oncol. 2020;6:1327–9. [DOI] [PubMed]
Tella SH, Kommalapati A, Alberts SR, McWilliams R, Mahipal A. Collateral damage of COVID-19 pandemic on oncology clinical trials.Chin Clin Oncol. 2020;9:80. [DOI] [PubMed]
Wosik J, Fudim M, Cameron B, Gellad ZF, Cho A, Phinney D, et al. Telehealth transformation: COVID-19 and the rise of virtual care.J Am Med Inform Assoc. 2020;27:957–62. [DOI] [PubMed] [PMC]
Mooney M, McCaskill-Stevens W. Interim guidance for patients on clinical trials supported by the NCI cancer therapy evaluation program and the NCI community oncology research program; 2020.
Gensheimer MF, Yom SS, Soto N, Dignam JJ, Le QT, Machtay M, et al. Multicenter clinical cancer research after COVID-19: a perspective from NRG oncology.Int J Radiat Oncol Biol Phys. 2020;108:483–5. [DOI] [PubMed] [PMC]
de Las Heras B, Saini KS, Boyle F, Ades F, de Azambuja E, Bozovic-Spasojevic I, et al. Cancer treatment and research during the COVID-19 pandemic: experience of the first 6 months.Oncol Ther. 2020;8:171–82. [DOI] [PubMed] [PMC]
Sharpless NE. COVID-19 and cancer.Science. 2020;368:1290. [DOI] [PubMed]
